PROBEARS
LIVE

Serial Number

79364831

Owner

BIOMACARE GMBH

Attorney

Alexander Lazouski

Filing Date

Aug 13, 2022

Add to watchlist:

No watchlists yet
View on USPTO

PROBEARS Trademark

Serial Number: 79364831 • Registration: 7334122

PROBEARS is a trademark filed by BIOMACARE GMBH on August 13, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

BIOMACARE GMBH

Grafenberger Allee 293

Entity Type: 16

Trademark Details

Filing Date

August 13, 2022

Registration Date

March 26, 2024

Published for Opposition

January 9, 2024

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 2, 2024 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 10, 2024 FICS
FINAL DISPOSITION PROCESSED
Oct 10, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 27, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 26, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 26, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 9, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 9, 2024 PUBO
NOTIFICATION PROCESSED BY IB
Jan 8, 2024 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 20, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 20, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 20, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 7, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 16, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 15, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 15, 2023 TROA
REFUSAL PROCESSED BY IB
Aug 1, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 10, 2023 RFCS
REFUSAL PROCESSED BY MPU
Jul 10, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 2, 2023 RFCR
NON-FINAL ACTION WRITTEN
Jun 1, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 1, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 17, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 13, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 9, 2023 REPR